Mesenchymal stromal cells as rescue therapy in biologic-refractory psoriasis: insights from a case series.
Ontology highlight
ABSTRACT: Cytokine-targeted biologics have revolutionized the management of moderate-to-severe psoriasis; however, all available therapies have failed a growing number of patients. Mesenchymal stromal cells (MSCs), with their immunomodulatory properties, offer a novel therapeutic option. Here, we report the cases of three adult female patients with long-standing, severe plaque psoriasis who were refractory to multiple biologic therapies, and were consequently treated with two intravenous infusions of allogeneic umbilical cord-derived MSCs (UC-MSCs; 1.96 - 3.00 × 106 cells/kg) 1 week (W) apart. Two patients received UC-MSCs as monotherapy; one received them alongside etanercept. Upon relapse, two patients resumed their last failed biologic at W9, while one switched to a new biologic at W24
SUBMITTER: Lwin SM
PROVIDER: S-EPMC12440939 | biostudies-literature | 2025
REPOSITORIES: biostudies-literature
ACCESS DATA